Libivirumab
Libivirumab is a human monoclonal antibody directed against the hepatitis B virus.[1][2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Hepatitis B surface antigen |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6598H10232N1788O2060S46 |
Molar mass | 149039.65 g·mol−1 |
(what is this?) (verify) |
References
- WHO Drug Information
- Shouval D, Terrault N, Galun E, Samuel D, Gane E, Pruett T, et al. (2006). "Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatitis B Virus (Hbv) in Liver Transplant (Lt) Recipients". Hepatology. 44 (4): 188A–700A [196A]. doi:10.1002/hep.21395.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.